SHREE PHARMA

CRESAR CT 40 TABLET

Original price was: ₹96.62.Current price is: ₹86.95.

Category:

Description

About Cresar CT 40 Tablet

Cresar CT 40 Tablet belongs to the class of anti-hypertensives primarily taken to treat hypertension (high blood pressure). Hypertension or high blood pressure is a life-long or chronic condition in which the blood pressure against the artery wall becomes too high. It can lead to the risk of heart diseases, like heart attack and stroke.

Cresar CT 40 Tablet is a combination of Telmisartan (angiotensin II receptor antagonist) and Chlorthalidone (thiazide diuretic or water pill). Telmisartan is an angiotensin receptor blocker that helps to relax and widen the blood vessels (arteries). Chlorthalidone is a diuretic that prevents absorption of excess salt in the body, preventing fluid retention. Together it lowers blood pressure and prevents the risk of any future stroke, heart attack, and oedema (fluid retention).

You can take Cresar CT 40 Tablet with food or an empty stomach. It should be swallowed whole with a glass of water. Your doctor will advise you on how often you take your tablets based on your medical condition. In some cases, you may experience dizziness, feeling tired, skin ulcers, diarrhoea, nausea diarrhoea, back pain, and cold/flu symptoms. Most of these side effects of Cresar CT 40 Tablet do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.

Do not use potassium supplements or salt substitutes unless the doctor has told you. In rare cases, Cresar CT 40 Tablet can cause a condition that results in a skeletal muscle problem, leading to further kidney failure. If you notice unexplained muscle pain, dark colour urine, tenderness, or weakness, especially if you also have a fever or unexplained tiredness, immediately contact the doctor. If you suspect pregnancy while taking Cresar CT 40 Tablet , tell your doctor right away. Cresar CT 40 Tablet should not be taken if you are breastfeeding as Cresar CT 40 Tablet can pass into breast milk, so before starting Cresar CT 40 Tablet , you need to stop nursing or do not take Cresar CT 40 Tablet while breastfeeding. Besides this, you should not use the Cresar CT 40 Tablet if you are unable to urinate. If you have diabetes, do not use Cresar CT 40 Tablet with any medication that contains aliskiren (a blood pressure medicine). Before taking Cresar CT 40 Tablet , tell your doctor if you have ever had liver disease, kidney failure, glaucoma (increased eye pressure), high or low levels of magnesium or potassium in your blood, have allergies or asthma, lupus (an autoimmune disease), diabetes, or an allergy to penicillin or sulfa drugs.

Uses of Cresar CT 40 Tablet

Treatment of Hypertension (high blood pressure).

Medicinal Benefits

Cresar CT 40 Tablet belongs to the class of anti-hypertensives primarily taken to treat hypertension (high blood pressure). Cresar CT 40 Tablet is a combination of Telmisartan (angiotensin II receptor antagonist) and Chlorthalidone (thiazide diuretic or water pill). Cresar CT 40 Tablet works by relaxing and widening the blood vessels (arteries), making the heart more efficient at pumping blood throughout the body. It helps to lower high blood pressure, thus reduces the chances of future heart attack and stroke. Besides this, it prevents excessive water and electrolytes (like sodium, potassium, etc.) from the body through urine which can otherwise raise high blood pressure. In addition to this, Cresar CT 40 Tablet also reduces the future risk of any stroke or heart attack.

Directions for Use

Take Cresar CT 40 Tablet as advised by the doctor. Swallow it as a whole with a glass of water. Do not break, crush or chew it.

Storage

Store in a cool and dry place away from sunlight

Side Effects of Cresar CT 40 Tablet

  • Dizziness
  • Feeling tired
  • Nausea
  • Skin ulcers
  • Diarrhoea
  • Back pain
  • Cold/flu symptoms

Reviews

There are no reviews yet.

Be the first to review “CRESAR CT 40 TABLET”

Your email address will not be published. Required fields are marked *